PlainRecalls
FDA Drug Moderate Class II Terminated

Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4

Reported: February 22, 2017 Initiated: January 30, 2017 #D-0476-2017

Product Description

Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4

Reason for Recall

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

Details

Recalling Firm
Actavis Inc
Units Affected
499320 units
Distribution
Nationwide in US
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4. Recalled by Actavis Inc. Units affected: 499320 units.
Why was this product recalled?
Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 22, 2017. Severity: Moderate. Recall number: D-0476-2017.